Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases-Reference-Cited by-同舟云学术

Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases

Published:2017-02-26 Issue:8 Volume:45 Page:1043-1057
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Komaki Y.¹,Yamada A.¹,Komaki F.¹,Micic D.²,Ido A.³,Sakuraba A.¹^ORCID

Affiliation:

1. Section of Gastroenterology; Hepatology and Nutrition; Department of Medicine; The University of Chicago Medicine; Chicago USA

2. Division of Gastroenterology and Hepatology; Department of Medicine; Northwestern University Feinberg School of Medicine; Chicago USA

3. Digestive and Lifestyle Diseases; Kagoshima University Graduate School of Medical and Dental Sciences; Kagoshima Japan

Funder

Children's Cancer Association of Japan

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13990/fullpdf

Reference54 articles.

1. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution;Kuek;Postgrad Med J,2007

2. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis- a multinational cross-sectional study;Nast;Arch Dermatol Res,2013

3. Inequities in access to biologic and synthetic DMARDs across 46 European countries;Putrik;Ann Rheum Dis,2014

5. US Food and drug administration Information for consumers (biosimilars) 2015

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recomendaciones basadas en el manejo de pacientes con diagnóstico de enfermedad de Crohn en el contexto peruano. Documento de posición de la Asociación Peruana para el Estudio del Intestino (ASPEIN);Revista de Gastroenterología del Perú;2024-06-26

2. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study;Gastroenterología y Hepatología (English Edition);2024-06

3. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey;Journal of Clinical Medicine;2024-05-24

4. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22

5. Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease;Therapeutic Advances in Gastroenterology;2024-01